Generated by AI
TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. TG Therapeutics also advances a broader pipeline of therapies, including subcutaneous and intravenous formulations of ublituximab, along with investigational programs such as Azer-cel. Its portfolio is centered on immune-related and hematologic conditions, reflecting a business model built around specialty medicines that target B-cell activity. TG Therapeutics serves patients and healthcare providers in the United States and internationally through its marketed products and development-stage candidates.
Website3020 Carrington Mill Blvd.
Morrisville, NC, 27560
United States
The latest articles about TGTX.
TG Therapeutics (TGTX) just delivered third quarter 2026 results that combined robust revenue with much slimmer profits. The business also raised full year revenue guidance to about US$1b, which sharpened investor focus. The strong third quarter report and higher 2026 revenue outlook landed on a stock that has already been on a powerful run, with a 30 day share price return of 16.06% and a year to date share price gain of 119.47% at a recent US$64.26. The 3 year total shareholder return of...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Investors talking about TGTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.